Home › Research › Drug development
Commentary: Aducanumab-Related ARIA: Paean or Lament?
Wassef HR, Colletti PM.. Clinical nuclear medicine, 2022-05-11
Topic: Amyloid, tau and blood-test diagnosis
Abstract Høilund-Carlsen and colleagues raise important issues related to amyloid PET, diagnosis of Alzheimer disease, and recently approved antiamyloid treatment aducanumab. We discuss new developments that may direct us to methods of presymptomatic detection of Alzheimer disease and development of effective prevention and therapy.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wassef, H. R., & Colletti, P. M. (2022). Commentary: Aducanumab-Related ARIA: Paean or Lament? Clinical nuclear medicine. https://doi.org/10.1097/rlu.0000000000004252
Vancouver
Wassef HR, Colletti PM. Commentary: Aducanumab-Related ARIA: Paean or Lament? Clinical nuclear medicine. 2022. doi:10.1097/rlu.0000000000004252. PMID: 35543641.
BibTeX
@article{wassef2022-35543641,
author = {Wassef, H. R. and Colletti, P. M.},
title = {{Commentary: Aducanumab-Related ARIA: Paean or Lament?}},
journal = {Clinical nuclear medicine},
year = {2022},
doi = {10.1097/rlu.0000000000004252},
pmid = {35543641},
url = {https://doi.org/10.1097/rlu.0000000000004252}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- We discuss new developments that may direct us to methods of presymptomatic detection of Alzheimer disease and development of effective prevention and therapy.
Why it matters
This commentary discusses issues raised about amyloid PET, the diagnosis of Alzheimer disease and the recently approved antiamyloid treatment aducanumab. It suggests new developments may point toward presymptomatic detection and the development of effective prevention and therapy.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 33/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Clinical nuclear medicine) |
| Journal's citation record | 1 / 4 | Clinical Nuclear Medicine: journal h-index 90 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.2 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 1 / 6 | Cited 0.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Patrick M. Colletti: h-index 7 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Southern California: institution h-index 1,521 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35543641) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 33 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Drug development
Also in Drug development
79 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.